ID

7555

Descripción

SOUTHWEST ONCOLOGY GROUPSUPPLEMENTARY OFF TREATMENT NOTICE (S0307) Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DEA67F10-B6B9-1C53-E034-0003BA12F5E7

Link

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DEA67F10-B6B9-1C53-E034-0003BA12F5E7

Palabras clave

Clinical Trial

Off-Treatment

C50.9

26/8/12 26/8/12 -
9/1/15 9/1/15 - Martin Dugas

Subido en

9 de enero de 2015

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0 Legacy

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Breast Cancer NCT00127205 Off Treatment - SOUTHWEST ONCOLOGY GROUPSUPPLEMENTARY OFF TREATMENT NOTICE (S0307) - 2287059v3.0

Detalles

No Instruction available.

1 formularios

StudyEvent: SOUTHWEST ONCOLOGY GROUPSUPPLEMENTARY OFF TREATMENT NOTICE (S0307)
1. No Instruction available.

Header

SWOG Patient ID

SWOG Study No.

Registration Step

Patient Initials (L, F M)

Institution/Affiliate

Physician

Participating Group Name

Participating Group Study No.

Participating Group Patient ID (Instructions: Submit this form after completion of end-of-study bone scan. If bone scan was not done, explain in Comments. All dates are MONTH, DAY, YEAR. Explain any blank fields or blank dates in the Comments section. Place an X in appropriate boxes. Circle AMENDED items in red and write AMENDED across top of form.)

Bone Scan

Did the patient have a bone scan after completion or discontinuation of protocol therapy?

Yes

date of bone scan (If yes,)

Bone metastases?

Yes

Patient Preference

If oral and intravenous bisphosphonates are equally effective in preventing breast cancer recurrence in the bone, which would the patient prefer to receive?

Oral (Oral)

Intravenous (Intravenous)

Comments

Volver a la parte superior de la página

Similar models

Show recommended models

ID